DK0871440T3 - Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister - Google Patents

Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister

Info

Publication number
DK0871440T3
DK0871440T3 DK96941518T DK96941518T DK0871440T3 DK 0871440 T3 DK0871440 T3 DK 0871440T3 DK 96941518 T DK96941518 T DK 96941518T DK 96941518 T DK96941518 T DK 96941518T DK 0871440 T3 DK0871440 T3 DK 0871440T3
Authority
DK
Denmark
Prior art keywords
schizophrenia
negative
treatment
cognitive symptoms
glycine uptake
Prior art date
Application number
DK96941518T
Other languages
English (en)
Inventor
Daniel C Javitt
Original Assignee
Daniel C Javitt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21731199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0871440(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daniel C Javitt filed Critical Daniel C Javitt
Application granted granted Critical
Publication of DK0871440T3 publication Critical patent/DK0871440T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK96941518T 1995-12-07 1996-12-05 Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister DK0871440T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US836195P 1995-12-07 1995-12-07

Publications (1)

Publication Number Publication Date
DK0871440T3 true DK0871440T3 (da) 2006-07-10

Family

ID=21731199

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96941518T DK0871440T3 (da) 1995-12-07 1996-12-05 Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister

Country Status (10)

Country Link
US (3) US5854286A (da)
EP (1) EP0871440B1 (da)
JP (3) JP2000501707A (da)
AT (1) ATE320804T1 (da)
DE (1) DE69635959T2 (da)
DK (1) DK0871440T3 (da)
ES (1) ES2260773T3 (da)
IL (1) IL124536A (da)
PT (1) PT871440E (da)
WO (2) WO1997020552A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
EP1073432B1 (en) 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia
US6416975B1 (en) * 1998-11-12 2002-07-09 Gliatech, Inc. Human glycine transporter type 2
AU4361500A (en) * 1999-04-20 2000-11-02 Advocare International Llc Nutritional composition for improved cognitive performance
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
HRP20030696A2 (en) 2001-02-16 2005-04-30 NPS Allelix Corp. Allelix Neuroscience GlyT-1 INHIBITORS
US20020187544A1 (en) * 2001-04-05 2002-12-12 Wisconsin Alumni Research Foundation Uropathogenic E. coli D-serine detoxification operon
AU2003244205A1 (en) * 2002-07-04 2004-01-23 Mitsubishi Pharma Corporation Method of examining and diagnosing integration dysfunction syndrome
FR2843590B1 (fr) * 2002-08-14 2007-10-05 Prestwick Scient Capital Inc Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
PT1587789E (pt) * 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
EP1622868A1 (en) 2003-04-30 2006-02-08 H. Lundbeck A/S Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives
BRPI0413587A (pt) * 2003-08-21 2006-10-17 Lundbeck & Co As H usos de um composto e de um inibidor de glyt-1, composição farmacêutica, kit, e, método para o tratamento de doença
CA2547652A1 (en) * 2003-12-04 2005-06-16 The Research Foundation Of The City University Of New York Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
WO2005120487A2 (de) * 2004-06-11 2005-12-22 Egon Tech Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
US20060052454A1 (en) * 2004-08-09 2006-03-09 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of a wide range of health problems that result from underlying metabolic disorders
SI1830833T1 (sl) * 2004-12-16 2010-05-31 Janssen Pharmaceutica Nv Kombinacija inhibitorja glicinskega transporterja GlyT in antipsihotika za zdravljenje simptomovshizofrenije in tudi njena priprava in njena uporaba
WO2008013860A2 (en) * 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
HRP20130713T1 (en) 2007-03-19 2013-09-30 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
US20110263968A1 (en) * 2008-11-04 2011-10-27 Mclean Hospital Corporation Drug-Enhanced Neurofeedback
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CA2816609A1 (en) * 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
PL3325444T3 (pl) 2015-07-20 2021-12-06 Acadia Pharmaceuticals Inc. Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
MX393950B (es) 2017-06-12 2025-03-24 Glytech Llc Composicion y metodo para el tratamiento de la depresion y psicosis en humanos
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
JP7518765B2 (ja) 2017-11-22 2024-07-18 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ－セリンの重水素化類似体およびその使用
PL3737665T3 (pl) 2018-01-10 2026-04-20 XWPharma Ltd. Proleki ketaminy, ich kompozycje i zastosowania
WO2020150698A1 (en) * 2019-01-18 2020-07-23 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
CA3158912A1 (en) * 2019-11-18 2021-05-27 Societe Des Produits Nestle S.A. Compositions and methods for glutathione enhancement for use in brain health
EP4559522A3 (en) 2021-08-13 2025-07-16 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
JPH07103018B2 (ja) * 1988-09-16 1995-11-08 武田薬品工業株式会社 精神分裂病治療剤
JP2757960B2 (ja) * 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5179085A (en) * 1989-03-15 1993-01-12 Warner-Lambert Company N-substituted α-amino acids and derivatives thereof having pharmaceutical activity
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5756348A (en) 1991-11-12 1998-05-26 Synaptic Pharmaceutical Corporation DNA encoding a glycine transporter and uses thereof
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina

Also Published As

Publication number Publication date
DE69635959T2 (de) 2006-12-07
ATE320804T1 (de) 2006-04-15
JP2000501707A (ja) 2000-02-15
US5837730A (en) 1998-11-17
IL124536A (en) 2001-03-19
ES2260773T3 (es) 2006-11-01
IL124536A0 (en) 1998-12-06
PT871440E (pt) 2006-07-31
US6162827A (en) 2000-12-19
EP0871440A1 (en) 1998-10-21
WO1997020553A1 (en) 1997-06-12
WO1997020552A1 (en) 1997-06-12
JP5363152B2 (ja) 2013-12-11
JP2009167205A (ja) 2009-07-30
US5854286A (en) 1998-12-29
DE69635959D1 (de) 2006-05-11
JP2013056918A (ja) 2013-03-28
EP0871440B1 (en) 2006-03-22
EP0871440A4 (en) 1999-01-20

Similar Documents

Publication Publication Date Title
DK0871440T3 (da) Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
NO911624L (no) Farmasoeytiske forbindelser.
TR199900308T2 (xx) Tiyenopirimidinler
TW287160B (da)
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
DE3683528D1 (de) Tetrapyrrol-therapiemittel.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
UA41355C2 (uk) Засіб для лікування нейро-сніду
IE890518L (en) Tetrazole excitatory amino acid receptor antagonists
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
IE852596L (en) Peptides active on the cns
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
EP0688319A4 (en) 4-HYDROXY-3-NITRO-1,2-DIHYDROCHINOLIN-2-ONE AND THE USE THEREOF AS EXCITATIVE AMINO ACIDS AND GLYCINE RECEPTOR ANTAGONISTS
DE69412178D1 (de) Apparat zur Behandlung von Lagen
DK366380A (da) Anvendelsen af grp og salte deraf
ES2094930T3 (es) Nueva proteina inhibidora de trombina aislada de garrapatas.
EA199600048A3 (ru) N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции
CA2239624A1 (en) Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists